Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?

Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Leukemia Research - Volume 74, November 2018, Pages 55-56

Ahmet Emre Eskazan, Mario Tiribelli,